Clinical Scorecard: Timing of Stage 2 ROP May Help Identify High-Risk Eyes
At a Glance
| Category | Detail |
|---|---|
| Condition | Retinopathy of Prematurity (ROP) |
| Key Mechanisms | Diagnosis of stage 2 ROP at an earlier postmenstrual age (PMA) correlates with higher treatment rates and greater proportion of zone I disease. |
| Target Population | Infants diagnosed with stage 2 ROP |
| Care Setting | Neonatal intensive care units |
Key Highlights
- 43.6% of eyes diagnosed with stage 2 ROP required treatment.
- Treatment rates varied by PMA at diagnosis: 48.9% (31 to <34 weeks), 44.7% (34 to <38 weeks), 29.7% (≥38 weeks).
- Earlier diagnosis linked to higher likelihood of treatment and zone I disease.
- Median PMA at first treatment was lower for earlier diagnosed stage 2 ROP.
- 66% of eyes with type 2 ROP received treatment before meeting type 1 ROP criteria.
Guideline-Based Recommendations
Diagnosis
- Consider earlier diagnosis of stage 2 ROP to identify high-risk infants.
Management
- Current treatment decisions are based on stage, zone, and plus disease.
Monitoring & Follow-up
- Monitor infants diagnosed with stage 2 ROP closely for progression.
Risks
- Timing of diagnosis may influence treatment needs and outcomes.
Patient & Prescribing Data
Infants with stage 2 ROP in neonatal intensive care.
High rates of treatment among eyes with type 2 ROP suggest early intervention may be necessary.
Clinical Best Practices
- Evaluate the timing of stage 2 ROP diagnosis in treatment planning.
- Discuss the potential need for earlier treatment with clinical teams.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.